EVOKE PHARMA ($EVOK) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.49 per share, beating estimates of -$0.64 by $0.15. The company also reported revenue of $3,310,000, beating estimates of $3,145,680 by $164,320.
You can see Quiver Quantitative's $EVOK stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EVOKE PHARMA Insider Trading Activity
EVOKE PHARMA insiders have traded $EVOK stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EVOK stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC NANTAHALA sold 41 shares for an estimated $179
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EVOKE PHARMA Hedge Fund Activity
We have seen 0 institutional investors add shares of EVOKE PHARMA stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC removed 4,141 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $19,711
- VANGUARD GROUP INC removed 2,488 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $11,842
- TOWER RESEARCH CAPITAL LLC (TRC) removed 623 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,965
- BLACKROCK, INC. removed 122 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $580
- UBS GROUP AG removed 92 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $437
- MORGAN STANLEY removed 31 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $147
- BANK OF AMERICA CORP /DE/ removed 6 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $28
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
